Comparative Pharmacology
Head-to-head clinical analysis: MAXITROL versus PREDSULFAIR II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXITROL versus PREDSULFAIR II.
MAXITROL vs PREDSULFAIR II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Maxitrol is a combination of dexamethasone (corticosteroid), neomycin (aminoglycoside antibiotic), and polymyxin B (polymyxin antibiotic). Dexamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Neomycin binds to bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides.
Prednisolone is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators. Sulfonamide component provides bacteriostatic action via inhibition of dihydropteroate synthase in bacterial folate synthesis.
1-2 drops or 0.5-1 inch strip of ointment into the conjunctival sac every 4-6 hours; in severe cases, every 2-4 hours. Frequency may be reduced after improvement.
1-2 drops into the affected eye(s) every 4-6 hours; not to exceed 6 doses per day.
None Documented
None Documented
Neomycin: 2–3 h (topical) but prolonged in renal impairment. Polymyxin B: 6–7 h (topical). Dexamethasone: 3–4 h (topical). Clinical: systemic absorption minimal with intact epithelium; half-life may be prolonged with corneal abrasion or inflammation.
Terminal elimination half-life of prednisolone (active moiety): 2.1-3.5 hours; clinical context: duration of HPA axis suppression exceeds plasma half-life (12-36 hours).
Renal: neomycin 30–50%; polymyxin B <1%; dexamethasone <1%. Fecal: neomycin >50% (unabsorbed); polymyxin B >99% (unabsorbed); dexamethasone <5%. Biliary: negligible for all components.
Renal: 70-80% (30-50% as unchanged prednisolone, 20-30% as prednisone and inactive metabolites); Biliary/Fecal: 15-20%
Category C
Category C
Ophthalmic Corticosteroid/Antibiotic Combination
Ophthalmic Corticosteroid/Sulfonamide Combination